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Evaluation at scale of microbiome-
derived metabolites as biomarker  
of flavan-3-ol intake in 
epidemiological studies
Javier I. Ottaviani1, Redmond Fong2, Jennifer Kimball2, Jodi L. Ensunsa2, Abigail Britten3, 
Debora Lucarelli3, Robert Luben  4, Philip B. Grace5, Deborah H. Mawson5, Amy Tym5, 
Antonia Wierzbicki5, Kay-Tee Khaw4, Hagen Schroeter1 & Gunter G. C. Kuhnle  4,6
The accurate assessment of dietary intake is crucial to investigate the effect of diet on health. Currently 
used methods, relying on self-reporting and food composition data, are known to have limitations 
and might not be suitable to estimate the intake of many bioactive food components. An alternative 
are nutritional biomarkers, which can allow an unbiased assessment of intake. They require a careful 
evaluation of their suitability, including: (a) the availability of a precise, accurate and robust analytical 
method, (b) their specificity (c) a consistent relationship with actual intake. We have evaluated human 
metabolites of a microbiome-derived flavan-3-ol catabolite, 5-(3′,4′-dihydroxyphenyl)-[gamma]-
valerolactone (gVL), as biomarker of flavan-3-ol intake in large epidemiological studies. Flavan-3-ols 
are widely consumed plant bioactives, which have received considerable interest due to their potential 
ability to reduce CVD risk. The availability of authentic standards allowed the development of a 
validated high-throughput method suitable for large-scale studies. In dietary intervention studies, we 
could show that gVL metabolites are specific for flavan-3-ols present in tea, fruits, wine and cocoa-
derived products, with a strong correlation between intake and biomarker (Spearman’s r = 0.90). 
This biomarker will allow for the first time to estimate flavan-3-ol intake and further investigation of 
associations between intake and disease risk.
Flavan-3-ols are a group of phenolic compounds that have been under intensive investigation for their effect 
on vascular function and the potential to reduce the risk of cardio-vascular diseases1,2. Numerous small-scale, 
short-term studies using surrogate markers of health have been conducted, but it is not clear whether these results 
provide a reliable estimate of the effect on disease risk reduction and primary disease prevention in the general 
public3,4. This can only be achieved with large, long-term prospective observational epidemiological studies and 
intervention studies such as COSMOS (NCT02422745). The advantage of the former is that they can provide 
information about flavan-3-ol intake as part of the habitual diet and that they can make use of data or samples 
already collected. As of now, epidemiological studies on flavanols, which relied on the validity of the assessment 
of dietary intake and food content data bases5, have shown modest or no relationship between flavanol intake and 
a decreased risk of cardio-vascular diseases6. While dietary intake assessments are often based on a combination 
of dietary self-reporting and food-composition databases, this approach has well-known limitations7,8.
An alternative method for the assessment of dietary intake are nutritional biomarkers. They are objective and 
measurable characteristics of an individual that are indicative of the intake of a given nutrient or dietary constit-
uent9. Nutritional biomarkers can be broadly divided into two categories10–13: recovery biomarkers, that allow the 
accurate estimation of actual intake, such as the use of urinary nitrogen for protein intake14, and surrogate or con-
centration biomarkers that allow the ranking of a study population according to their intake in order to improve 
dietary assessment or investigate associations with disease risk. Most biomarkers currently used in the context of 
1Mars, Inc., McLean, VA, USA. 2Department of Nutrition, UC Davis, CA, USA. 3MRC Epidemiology Unit, University of 
Cambridge, Cambridge, UK. 4Department of Public Health and Primary Care, University of Cambridge, Cambridge, 
UK. 5LGC, Newmarket Road, Fordham, UK. 6Department of Food and Nutritional Sciences, University of Reading, 
Reading, UK. Correspondence and requests for materials should be addressed to G.G.C.K. (email: g.g.kuhnle@
reading.ac.uk)
Received: 19 March 2018
Accepted: 21 June 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENtIFIC REPORTS |  (2018) 8:9859  | DOI:10.1038/s41598-018-28333-w
assessing the intake of bioactives, belong to the latter category11,12. These nutritional biomarkers are often based 
on the concentration of specific metabolites of the compounds of interest in plasma, serum or urine, an approach 
that we have used previously for isoflavones15,16.
In recent years, various human flavan-3-ol metabolites have been identified17, and the microbial ring-fission 
catabolite 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (gVL)18,19, in particular its phase II metabolites gVL-
3′/4′-sulphate and gVL-3′/4′-O-glucuronide (gVLM), have emerged as strong candidates for a nutritional bio-
marker of flavan-3-ol intake in humans. This is in based on their pharmacokinetic characteristics, as their half-life 
is sufficient to result in steady-state like conditions with regular consumption17,20.
Here, we use criteria proposed by IARC10 and the Institute of Medicine (IOM)21 to evaluate the suitability of 
gVLM as a nutritional biomarker of flavan-3-ol intake, in particular that:
 i. gVLM can be measured accurately and precisely in the relevant human biospecimen, e. g. plasma or urine;
 ii. gVLM are specific for flavan-3-ols;
 iii. gVLM concentration or excretion reflect changes in dietary intake consistently and therefore are prognos-
tic of intake
Furthermore, for use in large-scale epidemiological studies, the analytical method should be robust and suit-
able for high-throughput analysis.
In this study, we use these criteria to investigate the suitability of gVLM, i.e. the sum of gVL-3′/4′-sulphate and 
gVL-3′/4′-O-glucuronide, as nutritional biomarkers of flavan-3-ol intake, and investigated whether or not it is 
suitable for the investigation of flavan-3-ol intake in large cohort studies.
Methods
Analytical method. gVL metabolites were analysed using UPLC-tandem MS. De novo synthesised 
authentic standards22,23 of the human gVL metabolites 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-sulphate, 
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-O-glucuronide, as well as an isotope labelled internal standard, 
13C2D2-5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-sulphate, were obtained from Analyticon (Analyticon 
Biotechnologies AG, Lichtenfels, Germany). Stock solutions were prepared in ethanol:water (70:30) and stored 
at −80 °C.
Flavan-3-ol-metabolite-free urine was obtained from human-volunteers on a low flavan-3-ol diet. This study 
was approved by the University of Reading Research Ethics Committee. All subjects gave their written informed 
consent to participate and all experiments were performed in accordance with relevant guidelines and regulations.
Spot urine samples (60 µL) and internal standard solutions (2.5 µM 13C2D2-5-(3′,4′-dihydroxyphenyl)- 
γ-valerolactone-3′-sulphate, 60 µL) were combined, filtered (Impact Protein Precipitation filter plate, 
Phenomenex, Macclesfield, UK) by centrifugation (500 × g) for 2 minutes at room temperature and stored at 
−20 °C until analysis. Sample preparation was automated for the analysis of EPIC Norfolk urine samples using a 
Hamilton Star robot (Hamilton, Bonaduz, Switzerland).
Samples were separated by liquid chromatography (Acquity, Waters, Elstree, UK) using a C18 column 
(Kinetex C18 200 × 2.1 mm, 1.7 µm, with 0.5 µm Krudcatcher, Phenomenex, Macclesfield, UK) and the condi-
tions described in Table 1.
Compounds were detected by electrospray ionisation tandem mass spectrometry (Applied Biosystems API 
4000, Sciex, Warrington, UK) in negative ion mode using the parameters shown in Table 2. The spray voltage was 
−4500 V and the source temperature was 600 °C.
Samples were quantified using calibration standards prepared in flavan-3-ol-metabolite free urine 
samples (standard concentrations [µM]: 0.1, 0.25, 10, 20, 30, 40, 50). 5-(3′,4′-dihydroxyphenyl)-γ-vale-
rolactone-3′-O-glucuronide and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-sulphate were quantified using 
the peak area ratios of analyte and 13C2D2-5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-sulphate.
Time [min]
methanol:acetonitrile (10:90, 
v/v)
0.1% aqueous formic 
acid
Initial 5 95
2.00 5 95
3.50 15 85
6.00 20.4 79.6
6.10 95 5
7.00 95 5
7.10 5 95
8.00 5 95
Injection volume 7 µL (nominally – adjusted when required)
Strong wash 40:30:30 Acetonitrile:Isopropanol:0.1% formic acid (aq)
Weak wash 95:5 Water:Methanol
Table 1. HPLC-conditions for sample separation (flow rate 0.5 mL/min; column temperature 25 °C).
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Each batch included two replicates of quality control samples with three different concentrations: low QC 
(0.3 µM), medium QC (25 µM) and high QC (38 µM). Usual acceptance criteria for each batch were that at least 
one QC at each concentration and four out of the six QCs were within 15% of the theoretical concentration.
The method was validated using flavan-3-ol-metabolite-free urine, spiked with the authentic stand-
ards 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-O-glucuronide and 5-(3′,4′-dihydroxyphenyl)-γ-vale-
rolactone-3′-sulphate to assess stability, specificity, matrix effects, precision and accuracy. The matrix effect was 
assessed by spiking flavan-3-ol-metabolite free urines from different sources with known amounts of analyte and 
internal standard and comparing their peak-area-ratio ratios. Method performance was assessed using data from 
quality control samples in 255 batches analysed.
Human intervention studies. Test materials. Test materials consisted of fruit-flavoured non-dairy drinks 
that contained either specific flavan-3-ols (specificity study) or varying amounts of flavan-3-ols derived from 
cocoa (4 levels for the intake amount escalation study). Test materials were freshly prepared on each study day. 
All test materials were matched regarding their macro- and micro-nutrient content, including theobromine and 
caffeine, as well as in their orosensory and physicochemical characteristics. Composition of test materials is listed 
in Table 3. All test materials were supplied by Mars, Incorporated (McLean, VA).
Study population. Healthy male adults between 25 and 60 years of age (specificity study) and between 25 and 
40 years of age (intake amount escalation study) were recruited by public advertisement in the city of Davis 
and surrounding areas (California, USA). Exclusion criteria included a body mass index (BMI) higher than 
30 kg/m2, blood pressure (BP) higher than 140/90 mmHg, allergies to peanut or cocoa, avoidance of caffein-
ated food products and beverages, a history of CVD, stroke, renal, hepatic, or thyroid disease, gastrointestinal 
tract disorders, previous gastrointestinal surgery (except appendectomy), the current intake of herbal-, plant- or 
botanical-containing dietary supplements, persons following vegan/vegetarian diet, and those adhering to an 
uncommon diet or a weight loss program. To determine eligibility, participants were asked to complete health- 
and lifestyle questionnaires, have their height, weight, and in-office BP determined, and to provide a blood sample 
for complete blood count (CBC), liver panel, lipid panel and metabolic panel assessments. Enrolled participants 
commenced the study protocol between 1–3 weeks after eligibility was determined. While participating in the 
study, volunteers were asked to maintain their typical daily activities and diet throughout the study. To control 
for potential dietary flavan-3-ol intake, volunteers were asked to follow a defined low-flavan-3-ol diet on the 
day prior to and during each study day. All volunteers were instructed on how to follow a low-flavan-3-ol diet, 
receiving foods containing low or negligible amounts of flavanols including the dinner for the night previous 
to the study day. Additionally, volunteers were asked to restrain from consuming alcohol, coffee, or any other 
caffeine-containing beverages for one day prior, and during, the study days. Volunteers were required to fast 
overnight (12 h water, ad libitum) before each study day.
Specificity study. In order to investigate the specificity of gVLM, the sum of gVL-3′/4′-sulphate and 
gVL-3′/4′-O-glucuronide, as nutritional biomarker of flavan-3-ol intake, we performed a dietary intervention 
study with different possible precursors of gVL. This study was randomized, double-masked and followed an 
8x -crossover desig n, in which volunteers were asked to consume test materials containing specific flavan-3-ols 
Analyte
Precursor 
ion [m/z]
Product 
ion [m/z]
Retention 
time [min]
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-sulphate 287 207 3.80
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-O-glucuronide 383 207 3.95
13C2D2-γ-valerolactone-3′-sulphate 291 211 3.78
Table 2. LC-MS parameters for analytes and internal standards. Compounds were detected in negative ion 
mode with a dwell time of 20 ms.
Values (mg/70 kg BW) Level 1 Level 2 Level 3 Level 4
Amount of CF 100.0 200.0 400.0 1000.0
Procyandins 81.7 163.3 326.7 816.7
(−)-Epicatechin 16.0 32.0 64.0 160.0
(+)-Catechin 0.4 0.9 1.8 4.4
(−)- Catechin 1.9 3.8 7.6 18.9
(+)-Epicatechin 0.0 0.0 0.0 0.0
Caffeine 18.1 18.4 19.1 21.1
Theobromine 97.6 97.3 96.9 95.6
Total calories 33.3 33.3 33.3 33.3
Total Carbohydrates 7.8 7.8 7.8 7.8
Sodium 6.7 6.7 6.7 6.7
Table 3. Composition of test materials.
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along with toast with cream cheese. The flavan-3-ols tested were: i) (−)-epicatechin ii) (−)-epigallocatechin, 
iii) (−)-epicatechin-3-O-gallate, iv) (−)-epigallocatechin-3-O-gallate (all compounds isolated from green 
tea, purity >99% and food grade), v) a 1:1:1: mixture of theaflavin-3-O-gallate, theaflavin-3′-O-gallate and 
theaflavin-3,3′-O-digallate, vi) thearubigins (all isolated from black tea, purity >95% and food grade) and vii) 
procyanidin B-2 ((−)-epicatechin-(4α4β)-(−)-epicatechin; isolated from cocoa, purity 91%). One additional 
visit included the consumption of the test material without any flavan-3-ol added (control day). The amount of 
(−)-epicatechin consumed per volunteer was 34.8 mg or 120 µmol, which is close to the mean intake amount of 
(−)-epicatechin consumed in the UK24. The amount of the rest of the flavan-3-ols was equimolar to the amount 
of (−)-epicatechin ingested, except for thearubigins, which were given in equal mg amounts to the theaflavin mix.
After intake, urine was collected over 24 h in two collection periods (from 0 h to 6 h post intake and 6 h to 24 h 
post intake), using a fresh container for each collection period with 20 ml of 2 M sodium acetate (pH = 4.5) and 
2 mL of 0.5% (w/v) thymol in isopropanol as preservatives. Volunteers returned containers upon completion of 
sample collection, and urine was stored at −80 °C until analysis. The minimum sample size required to detect a 
minimum change of 6 µmol of gVLM in 24 h-urine (equivalent to a 5% of the amount of flavanols ingested) was 
determined by pair-t test and imputing a standard deviation of 4 µmol. Volunteers were randomized to receive 
the 8 different test materials using computer-generated lists of random numbers via the randomly permuted block 
method. The allocation list was generated by a researcher not involved with the recruitment and allocation of par-
ticipants. We assessed 17 volunteers for eligibility, 12 volunteers were enrolled in the study, and 8 volunteers com-
pleted all 8 interventions with the rest of the enrolled volunteers completing <4 interventions. Participants, study 
nurses, and researchers assessing outcomes as well as researchers involved with the statistical analysis of data 
were masked to the specific nature of intervention. The initial recruitment started in August 2016, and the study 
was conducted from August 2016 to January 2017. This study protocol was approved by the Institutional Review 
Board of UC Davis. All subjects gave their written informed consent to participate and all experiments were 
performed in accordance with relevant guidelines and regulations. This study was registered as NCT03194620.
Intake amount escalation study. In order to investigate the association between flavan-3-ol intake and gVLM 
excretion, we conducted a dietary intervention study where participants consumed different amounts of 
flavan-3-ol. This study was randomized, double-masked and followed a 4 × -crossover design, in which volun-
teers consumed test materials containing four different amounts of flavan-3-ols from cocoa. These flavan-3-ols 
include (−)-epicatechin, (+)- and (−)-catechin and their oligomers, the procyanidins, with a degree of polymeri-
zation from 2 to 10 in a profile analogous to that naturally found in the seeds of Theobroma cacao L. On four sepa-
rate occasions, each volunteer consumed four different amounts of flavan-3-ols that ranged from 95 mg, including 
15 mg of (−)-epicatechin to 1424 mg, including 227 mg of (−)-epicatechin, which are amounts well within the 
range of intakes determined in the UK24. After intake, urine was collected over 24 h in 4 collection periods (from 
0 h to 4 h post intake, 4 h to 8 h post intake, 8 h to 12 h post intake and 12 h to 24 h post intake), using a fresh con-
tainer for each collection period with 20 ml of 2 M sodium acetate (pH = 4.5) and 2 mL of 0.5% (w/v) thymol in 
isopropanol as preservatives. Volunteers returned the container upon completion of sample collection, and urine 
was stored at −80 °C until analysis. The minimum sample size required to detect changes of 20 µmol of gVLM in 
24 h-urine after the intake of each test drink was determined by ANOVA and imputing a standard deviation of 
14 µmol. Volunteers were randomized to receive the four different test materials using computer-generated lists 
of random numbers via the randomly permuted block method. The allocation list was generated by a researcher 
not involved with the recruitment and allocation of participants. We assessed 20 volunteers for eligibility, and 14 
volunteers were finally enrolled and completed the study. Participants, study nurses, and researchers assessing 
outcomes as well as researchers involved with the statistical analysis of data were masked to the intervention. The 
initial recruitment started in April 2013, and the study was conducted from April to May 2013. This study proto-
col was approved by the Institutional Review Board of UC Davis. All subjects gave their written informed consent 
to participate and all experiments were performed in accordance with relevant guidelines and regulations. This 
study was registered as NCT03201822.
Sample analysis. Urine samples from human intervention studies (50 µL) were diluted with 100 µL of 100 µM 
3-methyl hippuric acid (internal standard) and analyzed by UPLC-MS within 24 h. Samples were separated on a 
Waters Acquity UPLC (Waters, Milford, MA, USA) with an autosampler cooled at 5 °C. The injection volume was 
37.5 µL. Chromatography was carried out at 25 °C using a 100 × 2.1 mm Kinetex C18 1.7 µm, reversed phase col-
umn with a krudcatcher (Phenomenex). The mobile phase, pumped at a flow rate of 0.5 mL/min, was (A) 5 mM 
ammonium formate (pH 2.9); and (B) acetonitrile/methanol (90:10, v/v). The gradient started with 5% B from 
0–2 min, then ramped to 17.5% from 2–3.5 min, and then to 22.5% from 3.5–6 min. Detection was achieved with 
a Waters Quattro Micromass spectrometer fitted with an electrospray interface (ESI; Waters). MS analysis was 
carried out in negative ionization mode by multiple reaction monitoring (MRM). Detection of gVL-3′-sulphate 
and -3′-O-glucuornide utilized transitions from 287 m/z to 207 m/z and 383 m/z to 207 m/z, respectively, and 
both with a dwell time of 0.02 s, a cone voltage of 32 V, and a collision energy of 20 V. Data processing was per-
formed using Masslynx software (Waters). MS conditions were set by tuning with the corresponding compound. 
Source and desolvation temperature were set at 150 °C and 500 °C, respectively, while desolvation and cone gas 
were set at 900 L/h and 30 L/h, respectively. In both ionization modes, capillary, cone, and lens voltage were set at 
4 kV, 30 V, and 1 V, respectively. The identification and quantification of the compounds were based on co-elution 
with authentic standards. The precision and accuracy of the method was better than 5% and 20%, respectively.
EPIC Norfolk. We have investigated the feasibility of using gVLM as a nutritional biomarker in a large obser-
vational cohort by applying the method developed in Section 2.1 to 5000 random spot urine samples of the EPIC 
Norfolk cohort25. Participants of this study (n = 25,639), healthy men and women between 40 and 75 years living 
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in and around Norwich, UK, were recruited between 1993 and 1997. Spot urine samples were collected during 
the baseline health examination and stored at −20 °C prior to analysis. The study was approved by the Norwich 
District Health Authority Ethics Committee, and all participants gave signed informed consent.
Statistical analyses. Associations between intake and biomarker were assessed with linear regression mod-
els using R 3.4.226 with the boot package27. Adjusted R2 estimates were obtained by bootstrapping (n = 10,000).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Analytical method validation and performance. The application of a biomarker for nutrient intake 
assessments requires a robust, validated analytical method, which is ideally suitable for automation and 
high-throughput analysis. The method developed here can be highly automated and adopted to a robotic sample 
preparation and analysis platform, which allows for the large-scale analysis of gVLM within an 8 minute run time. 
Figure 1 shows a typical chromatogram of gVL-3′/4′-sulphate and gVL-3′/4′-O-glucuornide. The precision and 
accuracy of the method was well within the usual GLP criteria of 15%, and long-term performance monitoring 
of 255 batches over more than 100 days showed a typical accuracy of better than 5% and a precision better than 
10% (Table 4). The estimated limit of detection (signal-to-noise ratio better than 5-to-1) was at least 0.1 µM. There 
was a strong matrix effect, which was adequately compensated for by the isotope-labelled internal standard. All 
compounds were tested for their stability in urine under different conditions, including at high temperature (six 
hours at 35 °C, 24 h hours at room temperature) and following four freeze-thaw cycles (−80 °C), and the extracted 
samples were tested for 72 h hours at 5 °C and seven days at −20 °C. All compounds were stable under these con-
ditions and showed no indication of deterioration.
In 5000 random spot urine samples of EPIC Norfolk, median (IQR) concentration of the candidate biomarker 
(i.e. the sum of gVL-3′/4′-sulphate and gVL-3′/4′-O-glucuornide) was 3 (0.8–10.1) µmol/L, and in 421 (8%) 
samples the biomarker concentration was below the lower limit of quantification (0.1 µmol/L). The distribution 
of biomarker concentrations (Fig. 2) was skewed to the right and virtually log-normal.
Specificity of 5-(3′,4′-dihydroxyphenyl)-[gamma]-valerolactone as candidate biomarker of 
flavan-3-ol intake. In humans, gVL is formed by the colonic microbiome from different flavan-3-ol precur-
sors18,19. However, flavan-3-ols are a complex group of compounds and there was insufficient information about 
the type of flavan-3-ol that results in the formation of gVL. We have therefore investigated the formation of gVL in 
humans following the consumption of different monomeric and oligomeric and steroisomeric flavan-3-ols. This 
study showed that the oral intake of (−)-epicatechin, (−)-epicatechin-3-O-gallate and procyanidin B-2 resulted 
in the formation and subsequent presence in urine of both, gVL-3′/4′-sulphate and gVL-3′/4′-O-glucuronide. 
However, the consumption of theaflavins, thearubigins, (−)-epigallocatechin and (−)-epigallocatechin-3-
O-gallate, did not result in the formation of gVL, thus did not contribute to the presence of any of the gVLM in 
urine. Notably, the intake of equimolar amounts of procyanidin B-2 and (−)-epicatechin-3-O-gallate resulted in 
similar amounts of gVL-3′/4′-sulphate and −3′/4′-O-glucuronide as (−)-epicatechin (Fig. 3). To further char-
acterize the specificity of gVLM, we have also re-analysed a subset of urine samples collected after the intake of 
Figure 1. Typical chromatogram of EPIC Norfolk spot urine sample, showing γ-valerolactone-3′/4′-O-
glucuronide (top, 3.9 minutes) and γ-valerolactone-3′-sulphate (bottom, 3.8 minutes) in urine.
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different (epi)catechin stereoisomers in humans28, demonstrating that all (epi)catechin stereoisomers also con-
tribute to the presence of gVL-3′/4′-sulphate and -3′/4′-O-glucuronide in urine (Fig. 3, insert). In summary, only 
flavan-3-ols with an intact (epi)catechin moiety can contribute to the formation of gVL and subsequently urinary 
gVLM (Fig. 4).
Mean (SD) [µM] %CV %RE Mean (SD) [µM] %CV %RE Mean (SD) [µM] %CV %RE
Low QC (0.30 µM) Medium QC (25 µM) High QC (38 µM)
5-(4′-hydroxyphenyl)-γ-valerolactone-3′-sulphate 0.29 (0.02) 8.2 −4.6 24.9 (1.1) 4.4 −0.3 37.9 (1.5) 3.9 −0.4
5-(4′-hydroxyphenyl)-γ-valerolactone-3′-O-glucuronide 0.30 (0.04) 11.9 −1.1 25.4 (2.2) 8.7 1.9 37.9 (2.9) 7.7 −0.3
Table 4. Long-time precision (%CV) and accuracy (%RE, difference of mean calculated concentration and 
nominal concentration, standardised by nominal concentration) based on 288 analysed batches.
Figure 2. Distribution of gVLM (sum of γ-valerolactone-3′/4′-sulfate and γ-valerolactone-3′/4′-O-
glucuronide) concentrations in 5000 random samples of EPIC Norfolk. The red bar indicates samples with 
concentration below the lower limit of quantification (0.1 µmol/L).
Figure 3. Urinary excretion of flavan-3-ol biomarker (gVLM, sum of γ-valerolactone-3′/4′-sulphate and O–
glucuronide) following the consumption of different flavan-3-ols (error bars show standard error; n = 12–8). 
*indicate statistically significant differences (p < 0.05; repeated measures ANOVA).
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Association between flavan-3-ol intake and gVLM. A strong and consistent association between 
flavan-3-ol intake and the gVLM is crucial for their use as biomarker of intake. We have therefore investigated 
this association using daily intakes in humans of up to 1400 mg/d of flavan-3-ols, which covers the entire range 
of flavan-3-ol intake observed in EPIC Norfolk (0–1200 mg/d6). The results of our intake amount-escalation 
study show a strong and consistent association between flavan-3-ol intake and 24 h urinary excretion of gVLM 
(R2 = 0.66; 95% CI 0.49; 0.80; Spearman’s rank correlation: ρ = 0.90; Pearson’s r = 0.81; Fig. 5). These associations 
were attenuated, but remained significant, when excluding flavan-3-ol amounts higher than the top decile of 
intake in EPIC Norfolk (325 mg/d), with R2 = 0.50 (95% CI 0.34; 0.70), a Spearman’s rank correlation coefficient 
of ρ = 0.82 and a Pearson’s r of r = 0.70. A similar attenuation was observed when excluding data for a flavan-3-ol 
intake of 0 mg/d (R2 = 0.49 (95% CI 0.25; 0.69), Spearman’s rank correlation coefficient ρ = 0.74; Pearson’s r of 
r = 0.70).
Figure 4. Flavan-3-ol precursors of the microbial metabolite 5-(3′/4′-dihydroxyphenyl)-γ-valerolactone (gVL). 
Only compounds with intact (epi)catechin moiety result in the formation of γVL by the intestinal microbiome. 
ECG, (−)-epicatechin-3-O-gallate; EGCG, (−)-epigallocatechin-3-O-gallate; EGC, (−)-epigallocatechin.
Figure 5. Association between flavan-3-ol intake and gVLM (sum of 5-(3′/4′-dihydroxyphenyl)-γ-
valerolactone-3′/4′-sulphate and O–glucuronide metabolites). Results from the intake-amount escalation study 
and regression analysis (R2 = 0.66; 95% CI 0.49; 0.80). The intake amount used is comparable with the estimated 
habitual intake in EPIC Norfolk6. For comparison, Pearson and Spearman correlation coefficients for other 
biomarkers are shown (†44; ‡55).
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Discussion
In this study, we have assessed the suitability of the 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (gVL) phase II 
metabolites, gVL-3′/4′-O-glucuronide and gVL-3′/4′-sulphate (gVLM), as nutritional biomarker of flavan-3-ol 
intake, using the criteria suggested by IARC10 and the Institute of Medicine (IOM)21. In the course of this assess-
ment, we (i) developed a robust, precise and accurate method to analyse at scale gVLM in urine samples, (ii) 
established which flavan-3-ols lead to the formation of gVLM in humans, and (iii) showed a consistent rela-
tionship between flavan-3-ol intake and urinary concentrations of gVLM. In the following section, we discuss 
whether or not gVLM meets each of these criteria.
Measurement of gVLM as nutritional biomarker. The application of a nutritional biomarker requires 
a robust, precise and accurate bioanalytical method to determine the biomarker in the respective biospecimen. 
Here, we use phase II metabolites of gVL, and their accurate quantification requires the availability of authentic 
standards as all other methods introduce bias. The most commonly used approach to date, the deconjugation with 
sulphatases and ß-glucuronidase enzymes, followed by the analysis of the aglycon, relies on the complete and con-
sistent hydrolysis of phase II metabolites. However, we and others have shown previously that this cannot be fully 
and consistently achieved for metabolites of flavan-3-ols29,30 and that the degree of hydrolysis is affected by reac-
tion conditions31. An alternative method not relying on hydrolysis is to identify metabolites by their characteristic 
tandem-MS fingerprint and to quantify them as aglycone. However, this also introduces large instrument- and 
method-dependent variability, which renders the results not suitable for biomarker analysis. Authentic standards 
thus remain the “gold standard” for the identification and quantification of these compounds32, and the develop-
ment of this method was therefore made possible by the availability of authentic standards22,23.
Isotope-labelled standards are often used in tandem mass spectrometry for quantification, especially as they 
can compensate for matrix effects33. However, this can be affected by slight differences in retention time between 
labelled and unlabelled standard34 due to the isotope effect35, resulting in an uncompensated or partially uncom-
pensated matrix effect. For gVLM, the matrix effects were adequately compensated and precision and accuracy 
for both compounds studied here were well within the accepted range with an error of less than 15%.
The validation of the method developed here was shown to be robust, accurate and precise, and has been val-
idated with reference to generally accepted standards36. Furthermore, with a run time of 8-minutes and an easily 
automatable sample preparation, we show that this method is suitable for robotic automation and therefore for 
the high-throughput analysis of samples for the application of this method to large-scale studies. The application 
to a random subset of samples collected from EPIC Norfolk shows that the validation range is sufficient to meas-
ure the biomarker in the majority of participants.
gVLM are specific for flavan-3-ols. While the relationship between nutritional biomarker and intake 
is often assessed11,12, there is a paucity of data on their specificity. Indeed, it is often tacitly assumed that 
structurally-related metabolites, such as, for example glucuronidated or sulphated forms, are sufficiently spe-
cific for individual compounds37,38, but this assumption is rarely proven out. Investigating specificity is especially 
important when developing a biomarker for a structurally diverse group of compounds, such as flavan-3-ols.
Flavan-3-ols are extensively metabolised by the colonic microbiome18,39, but many of the metabolites, such 
as hippuric acid and phenylacetic acids are also derived from many other precursors40, and therefore not suit-
able to assess their intake. Urinary gVLM in humans has been found only after the intake of flavan-3-ols, and 
not following the consumption of other flavonoids and polyphenols17–19. However, flavan-3-ols encompass a 
complex group of compounds (Fig. 3), and little was known about the contribution of specific flavan-3-ols to 
the presence of gVLM in urine. The results obtained here showed that human consumption of (−)-epicatechin, 
epicatechin-3-O-gallate and procyanidin B-2 resulted in the formation of gVL, whereas theaflavins, thearub-
igins, (−)-epigallocatechin and (−)-epigallocatechin-3-O-gallate did not. We also showed that the intake of 
(−)-epicatechin stereoisomers contributes to the presence of gVL, confirming previous reports17,18. The finding 
that epicatechin-3-O-galllate intake gives raise to gVLM in urine implies that epicatechin-3-O-galllate is hydro-
lysed after intake, and that the resulting epicatechin is subsequently converted into gVL by the colonic microbi-
ome. Thus, gallic acid esters of other (−)-epicatechin stereoisomers, like catechin-3-O-galllate, are likely to also 
undergo this transformation. Similarly, other dimeric procyanidins different from procyanidin B-2, like procyan-
idin B1 [(−)-epicatechin-(4αß)-(+)-catechin], should be expected to contribute to urinary gVLM.
The data available today does not allow for a direct assessment of whether or not procyanidins with a higher 
degree of polymerisation (DP > 2) contribute to urinary gVLM. However, our data show that only one of the 
(−)-epicatechin units in procyanidin B2 contributed to the presence of gVLM in urine, and it is likely that this 
will also be applicable to procyanidins with a higher degree of polymerisation, i.e. that if the terminal unit is a 
(epi)catechin moiety it gives rise to the formation of gVL. Taken together, our results show that urinary gVLM are 
specific for the intake of (−)-epicatechin and its stereoisomers, their 3-O-gallate esters and procyanidins.
Relationship between dietary intake and gVLM. The intended use of a nutritional biomarker is to 
provide data on dietary intake, and a consistent relationship between dietary intake of a given compound and 
its biomarker of intake is therefore crucial. This requires an accurate and precise estimate of actual intake, but 
many studies rely on intake assessments derived from self-reporting methods and food-composition data as 
reference to validate nutritional biomarkers41. This is done despite the known limitations of data derived from 
self-reporting and food-composition methods7,8, especially with regard to a high variability in food content41,42. 
An investigation of the intake-biomarker relationship should therefore either use duplicate diets with validated 
analytical methods to assess intake, or use defined dietary interventions. In this study, we have used dietary inter-
ventions for which detailed compositional data were available (Table 3), and our data show a strong and consistent 
association between flavan-3-ol intake and urinary gVLM levels. The R2 value of 0.66 and correlation coefficient 
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of 0.90 are comparable or better than that of many other well-accepted nutritional biomarkers43,44, and only mod-
erately attenuated when excluding upper extremes of intake. Importantly, this strong association was possible 
even in the context of expected inter-individual differences in the production of gVL45. In this manner, gVLM 
differs from other gut microbiome-derived flavonoid metabolites, like equol, which shows large inter-individual 
differences, even capable of distinguishing populations as equol producers and non-producers46. In this context, 
and limited by the rather small sample cohort studies, we have previously reported that gVL metabolites show 
inter-individual differences of 60% in humans47. This inter-individual variability of gVL metabolites is more com-
parable to that reported for other gut microbiome metabolites, like enterolatone and enterodiol48, which are well 
recognized biomarkers of lignan intake49.
Suitability of gVLM as nutritional biomarker of flavan-3-ol intake. Taken together our results 
show that gVLM fulfils the criteria set to evaluate candidate nutritional biomarkers, and that gVLM qualifies as 
a surrogate biomarker13 of flavan-3-ol intake. It therefore enables the ranking of participants according to their 
flavan-3-ol intake and thus enables investigations into associations with disease risk biomarkers10–12 or morbid-
ity/mortality endpoints. While the validation of gVLM has been conducted with 24 h urine samples, surrogate 
biomarkers can also rely on the use of spot urines. In this context, the plasma half-life of gVLM of approximately 
6 h, (6.3 ± 1.7 h for gVL-3′-sulphate and 3.1 ± 0.6 h for gVL-3′-O-glucuronide)17, is sufficient to reach steady-state 
conditions with regular intake, which is the case for most dietary sources of flavan-3-ols, such as tea and various 
fruit. Therefore, it can be expected that the urinary excretion of gVLM is sufficiently constant to allow the use 
of creatinine-adjusted50 biomarker concentration in spot urine samples. Indeed, data for enterolignans, colonic 
metabolites with similar half-lives (enterodiol, 4.4 ± 1.3 h; enterolactone 13 ± 5.6 h51) to that of gVLM, show very 
high correlation between spot and 24 h urine concentrations52. Frequent high flavan-3-ol intake will therefore 
result in consistently higher gVLM concentrations in spot urine than low or episodic intake.
The data presented here, in combination with pharmacokinetic data published previously17, therefore show 
that creatinine-adjusted gVLM concentration in spot urine samples can be used as nutritional biomarker of 
flavan-3-ol intake.
Conclusion
In this study, we have evaluated the suitability of the microbiome-derived flavan-3-ol metabolite, 
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (gVL), as nutritional biomarker for the assessment of flavan-3-ol 
intake in large-scale epidemiological studies. The development of this biomarker has been made possible by the 
availability of authentic standards to allow the quantification of the Phase II metabolites gVL-3′/4′- sulphate and 
gVL-3′/4′-O-glucuronide in urine. The method developed is suitable for automation and thus high-throughput 
analysis, and we have applied it to 5000 random samples of the EPIC Norfolk cohort. The results show that the 
biomarker is found in the majority of participants with a wide range of concentrations and a high variability, 
allowing for the ranking of participants according to flavanol-3-ol intake.
We could show that this nutritional biomarker is specific for a number of specific flavan-3-ols present in tea, 
fruits, wine and cocoa-derived products, which represent the main sources of flavan-3-ols in the diet53,54. Overall, 
the biomarker established here allows for a significantly improved approach in the investigation of the associ-
ations between flavan-3-ol intake and health outcomes in large-scale observational studies, thereby providing 
critical data in the context of developing potential dietary recommendations.
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